NCT00919061 - Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Extrahepatic Bile Duct CancerGallbladder Cancer

Interventions

DRUG

Gemcitabine

Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.

DRUG

Cisplatin

20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.

DRUG

Sorafenib

400 mg PO once a day continuously.

Trial Locations (1)

Memorial Sloan Kettering Cancer Center, New York